12.72
-0.04 (-0.31%)
| Penutupan Terdahulu | 12.76 |
| Buka | 12.69 |
| Jumlah Dagangan | 2,251,338 |
| Purata Dagangan (3B) | 2,131,248 |
| Modal Pasaran | 1,672,107,648 |
| Harga / Pendapatan (P/E TTM) | 84.80 |
| Harga / Pendapatan (P/E Ke hadapan) | 49.02 |
| Harga / Jualan (P/S) | 6.49 |
| Harga / Buku (P/B) | 2.46 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | 7.85% |
| Margin Operasi (TTM) | 15.24% |
| EPS Cair (TTM) | 0.150 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 16.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 23.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 37.36% |
| Nisbah Semasa (MRQ) | 13.23 |
| Aliran Tunai Operasi (OCF TTM) | 27.27 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 12.50 M |
| Pulangan Atas Aset (ROA TTM) | -0.38% |
| Pulangan Atas Ekuiti (ROE TTM) | 3.18% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Dynavax Technologies Corporatio | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.88 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.34% |
| % Dimiliki oleh Institusi | 104.71% |
| Julat 52 Minggu | ||
| Median | 29.00 (127.99%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Nov 2024 | 29.00 (127.99%) | Beli | 13.01 |
| 15 Oct 2024 | 29.00 (127.99%) | Beli | 10.76 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Nov 2024 | Pengumuman | Dynavax to Present at the 7th Annual Evercore HealthCONx Conference |
| 11 Nov 2024 | Pengumuman | Dynavax Announces $100 Million Accelerated Share Repurchase Program |
| 07 Nov 2024 | Pengumuman | Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates |
| 07 Nov 2024 | Pengumuman | Dynavax Announces $200 Million Share Repurchase Program |
| 29 Oct 2024 | Pengumuman | Dynavax Adopts Limited-Duration Stockholder Rights Plan |
| 24 Oct 2024 | Pengumuman | Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |